Preparing biologics for commercialization: strategies to reduce risk and optimize outcomes

Register Free: https://www.biopharminternational.com/bp_w/outcomes

Event Overview:
Given the risks and opportunities inherent in drug development, choosing the right late-phase strategy to optimize timelines and capacity, while remaining flexible enough for changing market conditions, presents a significant challenge to companies developing and commercializing biopharmaceutical products. Join us for an expert roundtable discussion highlighting new technologies and strategies to reduce risk and execute consistently.

Key Learning Objectives:

• How to remain flexible in the face of uncertain market demand
• Identify the best practices to a reliable execution
• Optimize the latest digital tools to reduce risk to your timelines

Who Should Attend:

• Director, C-suite, researcher/developer, VP

Speakers

Bradley Nichols
Lead Engineer
Manufacturing Sciences & Technology
Thermofisher Scientific

Bradley Nichols is a lead engineer in the Manufacturing Sciences & Technology group at Thermo Fisher Scientific. Bradley has previously held roles in manufacturing, and technology transfer. He holds a Bachelor of Chemical Engineering and Master of Chemical/Biological Engineering from University of Queensland, Australia.

Joao Paulo Mattos
Director, Global Process Validation and CMC Lead,
Biologics, Pharma Services
Thermofisher Scientific

Joao Paulo Mattos is Director of Global Process Validation and CMC Lead at Thermo Fisher Scientific and has responsibility for process validation and CMC strategy for late stage and commercial programs across six drug substance manufacturing and development sites located globally. Joao Paulo has previously held roles in manufacturing sciences, process validation, and technology transfer. Prior to joining Thermo Fisher Joao Paulo worked for Bluebird bio, TESARO, and Bristol-Myers Squibb. He holds a B.S. in Chemical-Biological Engineering from MIT, and a Ph.D in Bioengineering from Rice University.

Canping Jiang
Senior Director, Biologics Strategy and PMO
Thermofisher Scientific

As Senior Director, Biologics Strategy and PMO, Canping is responsible for strategy development and deployment for the Biologics drug substance Business Unit (BU) in the Pharmaceutical Service Group (PSG) at Thermo Fisher Scientific. Canping leads the strategic project management office, oversees the BU strategic project portfolio. Canping leads the global MSAT, oversees the standardization and improvement of key global programs such as tech transfer, process validation and manufacturing technology best practices across a network of manufacturing sites in North America, Europe and Asia-Pacific.Canping has more than 15 years of industrial experience in biologics process development, tech transfer and commercialization including 9 years at Biogen and 5 years at Bristol-Myers Squibb (BMS). Prior to joining Thermo Fisher, Canping was Director of Solothurn Manufacturing Science (MS) at Biogen, responsible for establishing the MS organization to support start-up of Biogen’s next-gen manufacturing facility in Solothurn, Switzerland.

Canping was closely involved and made important contributions in the CMC development and BLA approval of more than 4 biologics therapeutics at BMS and Biogen, including Nulojix, Yervoy, Eloctate and Aduhelm.

Register Free: https://www.biopharminternational.com/bp_w/outcomes